New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject

Publikation: Patent

Standard

New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject. / Van Nieuwenhze, Michael S. (Opfinder); Turner, William W. (Opfinder); Witztum, Joseph L. (Opfinder); Hartvigsen, Karsten (Opfinder).

Patentnummer: WO2012108990-A2.

Publikation: Patent

Harvard

Van Nieuwenhze, MS, Turner, WW, Witztum, JL & Hartvigsen, K, New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject, Patentnummer WO2012108990-A2.

APA

Van Nieuwenhze, M. S., Turner, W. W., Witztum, J. L., & Hartvigsen, K. (2012). New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject. (Patentnummer WO2012108990-A2).

Vancouver

Van Nieuwenhze MS, Turner WW, Witztum JL, Hartvigsen K, Opfindere. New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject. WO2012108990-A2. 2012.

Author

Van Nieuwenhze, Michael S. (Opfinder) ; Turner, William W. (Opfinder) ; Witztum, Joseph L. (Opfinder) ; Hartvigsen, Karsten (Opfinder). / New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject. Patentnummer: WO2012108990-A2.

Bibtex

@misc{a1d3cb929f774721a0682763ce2673f2,
title = "New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject",
abstract = "The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.",
author = "{Van Nieuwenhze}, {Michael S.} and Turner, {William W.} and Witztum, {Joseph L.} and Karsten Hartvigsen",
year = "2012",
language = "English",
type = "Patent",
note = "WO2012108990-A2; A61K-038/10",

}

RIS

TY - PAT

T1 - New peptide-phospholipid conjugate useful for treating or preventing atherosclerosis in subject

AU - Van Nieuwenhze, Michael S.

AU - Turner, William W.

AU - Witztum, Joseph L.

AU - Hartvigsen, Karsten

PY - 2012

Y1 - 2012

N2 - The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.

AB - The present invention provides a peptide-phospholipid conjugate of Formula 1 wherein: X is selected from the group consisting of -CR1R2-, -NR3-, -O-, -S-, and -S+(R3)-; Y is selected from the group consisting of a bond, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; Z is a peptide comprising 1 to 50 amino acids; R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl; and R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, haloalkyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, amino, ether, cycloamino, cycloether, aryl, heteroaryl, arylalkyl, heteroarylalkyl, hydroxyaryl, arylether, cycloalkyl, heterocycloalkyl, hydroxycycloalkyl, halocycloalkyl, and aminocycloalkyl.

M3 - Patent

M1 - WO2012108990-A2

Y2 - 2012/08/16

ER -

ID: 47721935